Due to the progressive nature of Type 2 diabetes, insulin therapy is often required to achieve glycemic control. When lifestyle modifications and treatment with metformin with or without other oral antidiabetic drugs (OADs) have failed to achieve normoglycemia, timely initiation of singledose basal insulin treatment is a convenient, effective, and recommended strategy. The development of the long-acting basal insulin analogs, insulin detemir (IDet) and insulin glargine (IGlar), has resulted in significant improvements in the management of Type 2 diabetes, and specifically, in reducing rates of hypoglycemia. However, hypoglycemia still remains a limiting factor in the intensification of insulin therapy. Combination regimens involving insulin and incretin-based therapies have resulted in improved glycemic control with a similar rate of hypoglycemia compared with insulin alone. Novel basal insulin analogs may also help address the unmet needs associated with basal insulin therapy. Insulin degludec (IDeg) is a basal insulin analog that offers an ultra-long duration of action of more than 42 hours in adults, more flexibility compared with other long-acting insulin analogs in terms of daily dosing times, and reduced rates of hypoglycemia. Pegylated (PEG) lispro, an agent that is currently in clinical development, also offers an extended duration of action. The potential for fewer hypoglycemic episodes offered by combined regimens and new agents may improve adherence to insulin regimens.
Consequently, a substantial number of patients need insulin therapy after nine or more years of disease. 2 Advances in insulin therapy and other medications for the management of Type 2 diabetes have resulted in substantial improvements in glycemic control. However, these advances have not eliminated the psychologic and social burdens of the disease, such as fear of future complications and of hypoglycemia. 3 While the patient's attitude toward managing their treatment regimen is crucial to maintaining glycemic control, 4, 5 adherence to insulin, in particular, is poor in Type 2 diabetes. 6 The requirement to inject current formulations of basal insulin analogs at a fixed time each day may negatively affect treatment adherence and patients' quality of life (QoL) due to the complexity of the insulin regimen, needle phobia, the social stigma of having to inject insulin in public, and the risk for hypoglycemia. [7] [8] [9] [10] The American Association of Clinical Endocrinologists (AACE)/American
College of Endocrinology (ACE) consensus panel has recommended that hypoglycemia be avoided where possible. 11 The need remains for advances in current diabetes therapies that provide effective glucose control, maintain a stable glucose profile, and allow for more flexible treatment regimens that minimize side effects, particularly the risk for hypoglycemia.
This article aims to highlight advances in insulin therapy that aim to 
Advances in Basal Insulin Analog Therapy
A summary of insulin analogs currently in use for glycemic control in Type 2 diabetes is shown in Table 1 . Prior to the development of basal insulin analogs, neutral protamine Hagedorn (NPH), a suspension of crystalline zinc insulin combined with the positively charged polypeptide, protamine, was commonly used to provide basal glucose control. It has an onset of action beginning about 2 hours following injection, with a peak effect 4-6 hours after injection, and a duration of action of more than 12 hours. The resulting 'dome-shaped' basal plasma profile confers a risk for hypoglycemia at the peak insulin concentration and hyperglycemia at the trough. Long-acting basal insulin analogs have become important treatment options in Type 2 diabetes. The aim in developing such analogs has been to prolong the absorption kinetics to produce an absorption profile similar to that of endogenous basal insulin secretion. The flatter pharmacodynamic profile promotes a lower peak, a prolonged duration of action, and a slow and continuous absorption of insulin in the body that results in significant benefits in terms of glycemic control, flexibility of administration, and a reduced incidence of hypoglycemia compared with NPH (see Figure   1 ). [13] [14] [15] Long-acting insulin analogs also have the advantage of providing a more consistent glucose-lowering effect throughout the day compared with shorter-acting insulin analogs. Other advances include biphasic insulin analogs, which consist of a mixture of a soluble and a protaminated form of the rapid-acting analog, have shown improved postprandial glucose (PPG) control and a reduced risk for hypoglycemia compared with human premix formulations.
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Limitations of Basal Insulin Analog Therapy
Despite the reduced frequency of hypoglycemia associated with long-acting basal insulin analog therapy, hypoglycemia remains the major limiting factor in the treatment of Type 2 diabetes. 22 The fear of hypoglycemia can delay the initiation of insulin; 23 nocturnal hypoglycemia is of particular concern because many episodes are asymptomatic and may remain undetected until they become severe, which may lead to unconsciousness and even death. 24 A recent survey of patients with Type 2 diabetes using basal insulin analogs (n=3,042) found that more than a third (36 %) had experienced HEs during the previous 30 days. 25 Nonsevere HEs (NSHEs) may invoke a considerable economic burden for employers and patients, in addition to negatively impacting sleep quality, daytime functioning, and diabetes management among patients. 26 Patients took an average of half a day to respond to and recover from an NSHE, and monitored their glucose an average 5.7 extra times over the following week. 28 In addition to its effect on day-to-day living, hypoglycemia can also have serious health consequences. Acute hypoglycemia causes the brain to become neuroglycopenic and promote secretion of counter-regulatory hormones -primarily adrenaline and norepinephrine. In healthy young adults, these effects are transient and have no obvious detrimental consequences. However, people with endothelial dysfunction are at an increased risk for localized tissue ischemia, which can alter a patient's 33 HEs also result in impaired nutrient delivery to the brain, and may downregulate markers of neuronal plasticity and increase levels of neurotoxic glutamate, increasing the risk for dementia.
A history of severe HEs has been associated with an increased risk for dementia in older patients with Type 2 diabetes. 34 In summary, it is clear that hypoglycemia remains a serious challenge to patients taking basal insulin analogs, which highlights the need for basal insulin therapies that offer effective glycemic control while minimizing the risk for hypoglycemia.
Recent Advances in Managing Hypoglycemia in Type 2 Diabetes with Combination Regimens Involving Basal Insulin Analogs
Incretin-based therapies offer an effective new approach to the management of diabetes: GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. Because of their glucose-dependent mechanism of action -they stimulate insulin secretion only during hyperglycemia -incretin-based therapies have a low hypoglycemia risk.
As a result of their complementary mechanisms of action, basal insulin analogs are increasingly used in combination with GLP-1 receptor agonists. 35 Two GLP-1 receptor agonists are currently approved by the uS Food and Drink Administration (FDA): exenatide (Byetta ® , Bydureon ® , Amylin Pharmaceuticals), 36 and liraglutide, (Victoza ® , Novo Nordisk). 37 Several studies have investigated the efficacy and safety of the combination of GLP-1 receptor agonists and basal insulin; a summary appears in Table 2 . All studies to date have shown that the combination of exenatide and insulin, with or without oral antidiabetes drugs, showed significant improvements in glycemic control with low incidences of hypoglycemia, often leading to dose reduction, or even discontinuation, of insulin. However, it must be noted that most of these studies were small, and most were either observational or retrospective. Increased reports of gastrointestinal (GI) side effects associated with the use of GLP-1 receptor agonists resulted in the discontinuation of a minority of patients in each of the studies. [38] [39] [40] Although there are limited data comparing the rates of hypoglycemia in combined basal insulin regimens with those in monotherapy, the combination of GLP-1 receptor agonists and basal insulin has been associated with high patient satisfaction and low rates of hypoglycemia. 41 Other combined therapeutic regimens that are being studied include the combination of insulin therapy with other incretin-based therapies. analogs, with low levels of hypoglycemia reported (see Table 2 ). 
DPP-4 inhibitors are oral therapies that improve glycemic control in
Future Developments in Insulin Therapy
Recent research in insulin therapy has focused on the development of basal insulin analogs with an ultra-long duration of action. IDeg has a Figure 2 ).
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A meta-analysis of clinical trials in the IDeg development program confirmed that similar levels of glycemic control were achieved with fewer hypoglycemic episodes, particularly nocturnal episodes, with IDeg compared with IGlar, across a broad spectrum of patients with diabetes. 47 Since postprandial hyperglycemia contributes substantially to overall glycemia, initiating basal insulin therapy in combination with a rapid-acting insulin in one injection presents a convenient approach to achieving and sustaining optimal glycemic control. 
Summary and Concluding Remarks
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